Abstracts tagged "B cells"

Abstract Number: 2754 • 2017 ACR/ARHP Annual Meeting
Comparison of Individually Tailored Vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions: Results of a Prospective, Randomized–Controlled, Phase 3 Trial
Pierre Charles¹, Benjamin Terrier², Elodie Perrodeau³, Pascal Cohen², Stanislas Faguer⁴, Antoine Huart⁵, Mohamed Hamidou⁶, Christian Agard⁷, Bernard Bonnotte⁸, Maxime Samson⁸, Alexandre Karras⁹, Noémie Jourde-Chiche¹⁰, François Lifermann¹¹, Pierre Gobert¹², Catherine Hanrotel-Saliou¹³, Pascal Godmer¹⁴, Nicolas Martin Silva¹⁵, Grégory Pugnet¹⁶, Marie Matignon¹⁷, Olivier Aumaître¹⁸, Estibaliz Lazaro¹⁹, Xavier Puéchal²⁰, Philippe Ravaud²¹, Luc Mouthon²² and Loïc Guillevin²⁰, ¹Service de Médecine Interne, Hôpital Cochin, Paris, France, ²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁴2Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France, ⁵CHU, Toulouse, France, ⁶Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁸Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁹Nephrology, HEGP, Paris, France, ¹⁰Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ¹¹Dax, Dax, France, ¹²Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹³Brest, Brest, France, ¹⁴Medecine Interne, CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Caen University Hospital, Caen, France, ¹⁶Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ¹⁷Service de Néphrologie, Hôpital Henri-Mondor, Créteil, Créteil, France, ¹⁸CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ¹⁹service de médecine interne et maladies infectieuses, CHU de Bordeaux, Pessac, France, ²⁰National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²¹Hôpital Hôtel Dieu, Paris, France, ²²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: Once ANCA-associated vasculitis (AAV) remission was obtained, rituximab (RTX) superiority to azathioprine (AZA) to maintain remission was shown.1 In that study, at month 28,…
Abstract Number: 33 • 2017 ACR/ARHP Annual Meeting
B Cell Abnormalities in Patients with Chronic Cutaneous Lupus Erythematosus
Chungwen Wei¹, Aisha Hill², Kira Smith³, Ignacio Sanz¹, S. Sam Lim⁴ and Cristina Drenkard⁴, ¹Medicine, Emory University School of Medicine, Atlanta, GA, ²Medicine, Emory University School of Medicine, atlanta, GA, ³Emory University School of Medicine, Atlanta, GA, ⁴Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Lupus is a spectrum of disease with cutaneous lupus (CLE) without systemic features on one end and systemic lupus erythematosus (SLE) on the other.…
Abstract Number: 834 • 2017 ACR/ARHP Annual Meeting
Citrulline-Polyspecific B Cell Antigen Receptors Arising from Somatic Hypermutation within Clades Demonstrate Pathogenicity in Rheumatoid Arthritis
Philip J. Titcombe^1,2, Gustaf Wigerblad³, Natalie Sippl³, Na Zhang¹, Anna K. Shmagel⁴, Peter Sahlström⁵, Yue Jack Zhang¹, Laura Barsness Motschenbacher¹, Yogita Ghodke-Puranik⁶, Monika Hansson⁷, Lena Israelsson⁵, Timothy B. Niewold⁸, Lars Klareskog⁹, Camilla Svensson¹⁰, Khaled Amara⁷, Vivianne Malmström¹¹ and Daniel L. Mueller¹, ¹Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ²Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, ⁵Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁶Colton Center for Autoimmunity, New York University, New York, NY, ⁷Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology and Immunology, Mayo Clinic, Rochester, MN, ⁹Rheumatology unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹⁰Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, ¹¹Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Citrulline–modified proteins arising from the post-translational modification of arginine residues are recognized as primary rheumatoid arthritis (RA) autoantigen targets based on the strong association…
Abstract Number: 2872 • 2017 ACR/ARHP Annual Meeting
Elevated mTORC1 Signature in B Cells from Sjögren’s Syndrome Patients: mTOR Inhibition As a Novel Therapeutic Strategy to Halt B Cell Hyperactivity
Sofie L.M. Blokland^1,2, Maarten R. Hillen^3,4, Rina G.K. Kommer-Wichers⁴, Aike A. Kruize², Timothy R.D.J. Radstake^2,5, Jasper C.A. Broen^2,4 and Joel A.G. van Roon^2,4, ¹Rheumatology & Clinical Immunology/ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁵Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: A hallmark feature of primary Sjögren’s syndrome (pSS) is B cell hyperactivity, including presence of autoantibodies, aberrant presence of B cells and plasma cells…
Abstract Number: 34 • 2017 ACR/ARHP Annual Meeting
IL-23 Regulates Development of Spontaneous Germinal Centers and Pathogenic Autoantibody Production in BXD2 Mice
Huixian Hong¹, Qi Wu², PingAr Yang², Bao Luo³, Jun Li⁴, Hao Li⁵, Daniel Cua⁶, Hui-Chen Hsu² and John D. Mountz^2,7, ¹University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ³DIvision of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ⁵Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁶Discovery Research, Merck Research Laboratory, Palo Alto, CA, ⁷University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL
Background/Purpose: Targeting IL-23 to treat autoimmune disease and chronic inflammation is currently in development based on its pro-inflammatory function via regulating the activation of Th17…
Abstract Number: 835 • 2017 ACR/ARHP Annual Meeting
Generation of an Efficient CRISPR-Cas9 Editing Technique in Human Primary B Cells for the Targeted Study of Autoimmune Susceptibility Genes
Yuriy Baglaenko¹, Dario Ferri², Juan Carlos Zuniga-Pflucker³ and Joan E. Wither^2,4,5, ¹Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Immunology, University of Toronto, Toronto, ON, Canada, ³Biological Sciences, Sunnybrook Research Institute, Toronto, ON, Canada, ⁴Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Autoimmunity is a complex, poly-genic disorder that culminates in multi-organ damage. In systemic lupus erythematosus (SLE), the prototypic autoimmune disorder, a breakdown of tolerance…
Abstract Number: 2874 • 2017 ACR/ARHP Annual Meeting
Thymic Stromal Lymphopoietin (TSLP) Expression Is Associated with Lymphoproliferation and Lymphoma in Primary Sjögren’s Syndrome
Saviana Gandolfo¹, Cinzia Fabro¹, Michela Bulfoni², Sabino Russi³, Luca Quartuccio¹, Domenico Ettore Sansonno³, Carla Di Loreto², Daniela Cesselli² and Salvatore De Vita¹, ¹Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ²Institute of Anatomic Pathology, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ³Department of Biomedical Sciences and Human Oncology, University of Bari, Italy, Bari, Italy
Background/Purpose: Primary Sjögren’s syndrome (pSS) is an autoimmune and lymphoproliferative systemic disease with B cell hyperactivity and increased risk of non-Hodgkin lymphoma (NHL) evolution. In…
Abstract Number: 35 • 2017 ACR/ARHP Annual Meeting
B-Cell Subset Differences in Inflammatory Rheumatic Diseases
Joao Lagoas Gomes^1,2, Dario Ligeiro³, Alice Lima³, Cristina Teixeira³, Alexandre Sepriano^4,5, Sofia Ramiro⁶, Carina Lopes⁷, Tiago Costa⁸, Manuela Costa⁸, Jaime Cunha Branco^1,2 and Fernando Pimentel-Santos^1,2, ¹Rheumatology, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal, ²CEDOC, NOVA Medical School, Lisbon, Portugal, ³Centro de Sangue e Transplantação de Lisboa, Instituto Português do Sangue e Transplantação (IPST), I.P, Lisbon, Portugal, ⁴CEDOC, NOVA Medical School, Lisboa, Portugal, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁷Hospital de Egas Moniz-CHLO, Lisbon, Portugal, ⁸Rheumatology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal
Background/Purpose: Targeting humoral immunity has been proved effective in several inflammatory rheumatic diseases (IRD). Though clinical trials have shown some efficacy of B-cell depletion in…
Abstract Number: 886 • 2017 ACR/ARHP Annual Meeting
CC-220 Decreases B-Cell Subsets and Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus (SLE) Patients and Is Associated with Skin Improvement: Pharmacodynamic Results from a Phase IIa Proof of Concept Study
Victoria P Werth¹, Richard Furie², Allison Gaudy³, Ying Ye³, Shimon Korish³, Nikolay Delev³, Douglas Hough³, Michael Weiswasser³, Suktae Choi³ and Peter Schafer³, ¹University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ²Northwell Health, Great Neck, NY, ³Celgene Corporation, Summit, NJ
Background/Purpose: CC-220 is a high affinity ligand for cereblon with immunomodulatory properties, currently in development for the treatment of Systemic Lupus Erythematosus as well as…
Abstract Number: 2974 • 2017 ACR/ARHP Annual Meeting
B Cell Binding Autoreactive VH4.34 Antibodies Are Specific to Lupus, Consist of Diverse Isotypes, and Are Associated with High Disease Activity and Lupus Nephritis
Scott Jenks¹, Joseph Marcus², Kevin Cashman¹ and Ignacio Sanz³, ¹Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, ²San Antonio Uniformed Services Health Education Consortium, San Antonio, TX, ³Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA
Background/Purpose: SLE is characterized by the dysregulation of humoral immunity including high levels of autoreactive IgG VH4.34 antibodies recognized by the rat anti-human idiotypic antibody…
Abstract Number: 36 • 2017 ACR/ARHP Annual Meeting
GM-CSF-Producing B Cells: A Novel B Cell Subset Involved in the Pathogenesis of Systemic Sclerosis
Kazuhiko Higashioka¹, Yuri Ota¹, Tsuyoshi Nakayama¹, Koji Mishima¹, Masahiro Ayano¹, Yasutaka Kimoto², Hiroki Mitoma¹, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi³ and Hiroaki Niro⁴, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Systemic sclerosis (SSc) is a T helper type 2 (Th2)-driven autoimmune disease characterized by vasculopathy and fibrosis. There are still unmet needs in the…
Abstract Number: 949 • 2017 ACR/ARHP Annual Meeting
Sequence Homology and Immune Reactivity between T Cell Epitopes of Related Gut Microbes and Two Novel Autoantigens Provide a Link between Microbial and Host Immunity in Patients with Rheumatoid Arthritis
Annalisa Pianta¹, Sheila Arvikar², Klemen Strle³, Elise E. Drouin¹, Qi Wang⁴, Catherine E. Costello⁴ and Allen C. Steere⁵, ¹Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, BOSTON, MA, ³Department of Immunology and Inflammatory Diseases, Massachusetts General Hospital, BOSTON, MA, ⁴Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, MA, ⁵Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: It has been proposed that immunological triggers at mucosal sites, such as the gut microbiota, may promote autoimmunity affecting joints in patients with rheumatoid…
Abstract Number: 38 • 2017 ACR/ARHP Annual Meeting
Cytokine Production By CpG-Activated B Cells Require Glutaminolysis to Drive mTOR Activation, Aerobic Glycolysis and Mitochondrial Respiration
Matthew Cheung¹, Dongyue Huang¹, Emily Liu², Jennifer Ra² and Alfred Kim³, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²IM/Rheumatology, Washington University School of Medicine, Saint Louis, MO, ³IM/Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: B cells contribute to disease pathophysiology through several mechanisms, including cytokine secretion. A wide variety of stimuli can activate B cells to produce cytokines…
Abstract Number: 1466 • 2017 ACR/ARHP Annual Meeting
The Effects of Rituximab and B-Cells Depletion on the Inflammatory and Pro-Thrombotic Profile of Leucocytes of Rheumatoid Arthritis Patients and on the Vascular Endothelium
Irene Cecchi¹, Carlos Perez-Sanchez², Patricia Ruiz-Limon³, Ivan Arias de la Rosa³, Maria Carmen Abalos-Aguilera³, Yolanda Jiménez-Gómez², Rafaela Ortega-Castro², Eduardo Collantes-Estévez², Alejandro Escudero-Contreras³, Massimo Radin⁴, Nuria Barbarroja², Dario Roccatello⁵, Savino Sciascia⁶ and Chary Lopez-Pedrera⁷, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁷IMIBIC/Reina Sofia Hospital/ University of Cordoba, Cordoba, Spain
Background/Purpose: Cardiovascular disease (CVD) constitutes a relevant cause of morbidity and mortality in Rheumatoid Arthritis (RA) patients. Rituximab (RTX) has been proved to be effective…
Abstract Number: 40 • 2017 ACR/ARHP Annual Meeting
B-Cell Attracting Chemokine-1 (BCA-1) and Macrophage Inflammatory Protein-3 Alpha (MIP-3α) Act Synergistically in the Recruitment of B Cells in the Rheumatoid Synovium
Estefanía Armas-González¹, María Jesús Domínguez-Luis², María Teresa Arce-Franco³, Javier Castro-Hernández³, Vanesa Hernandez⁴, Sagrario Bustabad⁵, Alberto Cantabrana-Alutiz⁶ and Federico Díaz-González⁷, ¹Universidad de La Laguna, Departamento de Medicina Física y Farmacología, Facultad de Medicina, La Laguna, Tenerife, Spain, ²Laboratorio de Reumatología. Hospital Universitario de Canarias, La Laguna, Spain, ³Laboratorio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ⁴Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, S/C Tenerife, Spain, ⁵Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ⁶Servicio de Reumatología. Hospital Universitario Nuestra Señora de Candelaria, La Laguna, Tenerife, Spain, ⁷Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: B cells are recognized as key players in the pathogenesis of rheumatoid arthritis (AR) through the production of autoantibodies, the local production of proinflammatory…

« Previous Page
1
…
5
6
7
8
9
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].